NewLink Genetics Corp. (NASDAQ:NLNK) fell 1.6% during mid-day trading on Tuesday . The stock traded as low as $10.03 and last traded at $10.15, with a volume of 93,302 shares. The stock had previously closed at $10.32.

Several research firms recently issued reports on NLNK. Zacks Investment Research downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Robert W. Baird reaffirmed a “buy” rating on shares of NewLink Genetics Corp. in a research note on Monday, May 16th. Jefferies Group reaffirmed a “hold” rating and set a $10.00 price target on shares of NewLink Genetics Corp. in a research note on Wednesday, May 11th. SunTrust Banks Inc. lowered shares of NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $59.00 to $12.00 in a report on Tuesday, May 10th. Finally, Mizuho decreased their price objective on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $23.29.

The firm’s market capitalization is $289.40 million. The company’s 50-day moving average is $10.82 and its 200-day moving average is $14.48.

NewLink Genetics Corp. (NASDAQ:NLNK) last issued its quarterly earnings data on Friday, July 29th. The company reported ($1.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.35. On average, equities research analysts anticipate that NewLink Genetics Corp. will post ($3.06) earnings per share for the current fiscal year.

An institutional investor recently raised its position in NewLink Genetics Corp. stock. Dimensional Fund Advisors LP boosted its position in NewLink Genetics Corp. (NASDAQ:NLNK) by 0.6% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 48,507 shares of the company’s stock after buying an additional 300 shares during the period. Dimensional Fund Advisors LP owned about 0.17% of NewLink Genetics Corp. worth $1,765,000 at the end of the most recent reporting period.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.